JP6275239B2 - Ｈｍｗｐｅｇによる骨粗鬆症の管理 - Google Patents

Ｈｍｗｐｅｇによる骨粗鬆症の管理 Download PDF

Info

Publication number
JP6275239B2
JP6275239B2 JP2016502913A JP2016502913A JP6275239B2 JP 6275239 B2 JP6275239 B2 JP 6275239B2 JP 2016502913 A JP2016502913 A JP 2016502913A JP 2016502913 A JP2016502913 A JP 2016502913A JP 6275239 B2 JP6275239 B2 JP 6275239B2
Authority
JP
Japan
Prior art keywords
bone
polyethylene glycol
peg
hmw peg
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016502913A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513738A (ja
JP2016513738A5 (enExample
Inventor
リファット パムック，
リファット パムック，
ローラ レイ マケイブ，
ローラ レイ マケイブ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Michigan State University
Original Assignee
Michigan State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michigan State University filed Critical Michigan State University
Publication of JP2016513738A publication Critical patent/JP2016513738A/ja
Publication of JP2016513738A5 publication Critical patent/JP2016513738A5/ja
Application granted granted Critical
Publication of JP6275239B2 publication Critical patent/JP6275239B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016502913A 2013-03-15 2014-03-14 Ｈｍｗｐｅｇによる骨粗鬆症の管理 Active JP6275239B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361798481P 2013-03-15 2013-03-15
US61/798,481 2013-03-15
PCT/US2014/028832 WO2014144425A1 (en) 2013-03-15 2014-03-14 Managing osteoporosis with hmw peg

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017024048A Division JP2017082009A (ja) 2013-03-15 2017-02-13 Ｈｍｗ ｐｅｇによる骨粗鬆症の管理

Publications (3)

Publication Number Publication Date
JP2016513738A JP2016513738A (ja) 2016-05-16
JP2016513738A5 JP2016513738A5 (enExample) 2017-03-16
JP6275239B2 true JP6275239B2 (ja) 2018-02-07

Family

ID=51537706

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016502913A Active JP6275239B2 (ja) 2013-03-15 2014-03-14 Ｈｍｗｐｅｇによる骨粗鬆症の管理
JP2017024048A Withdrawn JP2017082009A (ja) 2013-03-15 2017-02-13 Ｈｍｗ ｐｅｇによる骨粗鬆症の管理
JP2018142353A Active JP6619849B2 (ja) 2013-03-15 2018-07-30 Ｈｍｗ ｐｅｇによる骨粗鬆症の管理

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017024048A Withdrawn JP2017082009A (ja) 2013-03-15 2017-02-13 Ｈｍｗ ｐｅｇによる骨粗鬆症の管理
JP2018142353A Active JP6619849B2 (ja) 2013-03-15 2018-07-30 Ｈｍｗ ｐｅｇによる骨粗鬆症の管理

Country Status (11)

Country Link
US (2) US10045949B2 (enExample)
EP (1) EP2968159B1 (enExample)
JP (3) JP6275239B2 (enExample)
AU (2) AU2014229082C1 (enExample)
CY (1) CY1122568T1 (enExample)
DK (1) DK2968159T3 (enExample)
ES (1) ES2744828T3 (enExample)
HU (1) HUE045032T2 (enExample)
PL (1) PL2968159T3 (enExample)
PT (1) PT2968159T (enExample)
WO (1) WO2014144425A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419823B (zh) * 2020-04-30 2022-03-29 上海公谊药业有限公司 一种延胡索酸泰妙菌素肠溶微丸及其制备方法和用途
NL1044084B1 (nl) 2021-07-05 2023-01-11 Evers Agro B V Mestinjecteur

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10338646A (ja) * 1996-08-26 1998-12-22 Takeda Chem Ind Ltd 骨形成促進医薬組成物
ATE544354T1 (de) * 2002-11-26 2012-02-15 Univ Chicago Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen
JPWO2004105825A1 (ja) * 2003-01-10 2006-07-20 多木化学株式会社 骨形成用生体材料、該材料を含む注入用製剤、及び該材料を調製するためのキット、並びにこれらを用いる骨形成方法
JP2007533755A (ja) * 2004-04-20 2007-11-22 ザ ユニヴァーシティ オヴ シカゴ 高分子量ｐｅｇ様化合物を含む治療薬送達システム
US8840933B2 (en) 2006-05-03 2014-09-23 Warsaw Orthopedic, Inc. Method of treating neuronal injury by administering magnesium chloride and PEG
US9675696B2 (en) * 2006-11-14 2017-06-13 Warsaw Orthopedic, Inc. Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain
US8153112B2 (en) 2007-08-03 2012-04-10 Warsaw Orthopedic, Inc. Compositions and methods for treating cavity conditions
MX2011009988A (es) * 2009-03-23 2011-11-18 Univ Chicago Metodos para la prevencion y el tratamiento de trastornos epiteliales inducidos por radiaciones.
EP2468265A3 (en) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogeneous preparations containing vitamin D

Also Published As

Publication number Publication date
EP2968159A1 (en) 2016-01-20
EP2968159B1 (en) 2019-06-12
CY1122568T1 (el) 2021-01-27
JP2016513738A (ja) 2016-05-16
US20160000730A1 (en) 2016-01-07
AU2014229082A1 (en) 2015-11-05
AU2018250501A1 (en) 2018-11-15
HUE045032T2 (hu) 2019-12-30
JP2017082009A (ja) 2017-05-18
JP6619849B2 (ja) 2019-12-11
AU2014229082C1 (en) 2019-01-17
JP2018162328A (ja) 2018-10-18
ES2744828T3 (es) 2020-02-26
DK2968159T3 (da) 2019-08-12
US10045949B2 (en) 2018-08-14
AU2018250501B2 (en) 2020-06-25
PT2968159T (pt) 2019-10-01
AU2014229082B2 (en) 2018-07-19
US20190015353A1 (en) 2019-01-17
PL2968159T3 (pl) 2019-11-29
WO2014144425A1 (en) 2014-09-18
EP2968159A4 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
Kempf et al. Colistin use and colistin resistance in bacteria from animals
Meganck et al. Evaluation of a protocol to reduce the incidence of neonatal calf diarrhoea on dairy herds
Litten-Brown et al. Porcine models for the metabolic syndrome, digestive and bone disorders: a general overview
Suthongsa et al. Effects of dietary levels of chito-oligosaccharide on ileal digestibility of nutrients, small intestinal morphology and crypt cell proliferation in weaned pigs
Harris et al. Inflammatory bowel disease causes reversible suppression of osteoblast and chondrocyte function in mice
Tomaszewska et al. Chronic dietary supplementation with kynurenic acid, a neuroactive metabolite of tryptophan, decreased body weight without negative influence on densitometry and mandibular bone biomechanical endurance in young rats
Wang et al. Dietary zinc glycine supplementation improves tibia quality of meat ducks by modulating the intestinal barrier and bone resorption
Tyagi Mechanism of action of gut microbiota and probiotic Lactobacillus rhamnosus GG on skeletal remodeling in mice
MXPA04004904A (es) Uso de glutamato, derivados o metabolitos de glutamato, analogos de glutamato o mezclas de los mismos para la preparacion de una composicion para el tratamiento de osteoporosis.
JP6619849B2 (ja) Ｈｍｗ ｐｅｇによる骨粗鬆症の管理
Díaz et al. Effect of feeding three lysine to energy diets on growth, body composition and age at puberty in replacement gilts
Barreiro et al. Densitometric and biochemical values of broiler tibias at different ages
Fuchs et al. A comparison of the carcase characteristics of pigs immunized with a ‘gonadotrophin-releasing factor (GnRF)’vaccine against boar taint with physically castrated pigs
Tang et al. Deletion of vitamin D receptor exacerbated temporomandibular joint pathological changes under abnormal mechanical stimulation
Harvey et al. Effect of daily lithium chloride administration on bone mass and strength in growing broiler chickens
Dumas et al. Effect of creep and post-weaning feeding composition on piglets’ intestinal health and post-weaning growth according to their creep feed consumption status
Zeni et al. Differences in bone turnover and skeletal response to thyroid hormone treatment between estrogen-depleted and repleted rats
Iesina et al. Pathoanatomical diagnosis, treatment and preventive measures at pigs gastroenterocolitis
Yan The effects of dietary probiotic inclusion on skeletal health of poultry and its possible mechanisms
Somagond et al. Effect of physical form of the therapeutic diet on the behaviour of crossbred calves experimentally infected with foot-and-mouth disease virus
KR20190100187A (ko) 다중 골연골종(mo)을 치료하는 방법
Tymczyna et al. Interrelationships between morphometric, densitometric, and mechanical properties of mandible in 6-month-old male pigs
Stacenko et al. Usage of “Feed Back” as an ecologically safe and effective means for preventing rotoviral infection of piglets
Esmaeili Effects of Probiotic Lactobacilli Administration During Pregnancy on the Bone of CD-1 Mouse Dams at Weaning
Hasan Chondronecrosis with Osteomyelitis in broilers: Bacterial species involvement and influence of Probiotics and Synbiotics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180109

R150 Certificate of patent or registration of utility model

Ref document number: 6275239

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250